Key facts
- It has raised $100K; the latest was Accelerator/Incubator in Oct 2025.
- Notable investors include Angels Capital, Incibe, Lanzadera Accelerator, Marina de Empresas, University of Valencia.
- Status: Privately Held (backing).
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for Evolving Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Evolving Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Evolving Therapeutics
Developer of a phage-based system designed for combating multi-resistant bacteria. The company offers customized tools for the prevention, treatment, and diagnosis of pathogenic bacteria using phages, including technical support and assistance services for research laboratories, enabling clients in human, animal, and plant health sectors to address bacterial infections resistant to conventional treatments.
- Sector
- Healthcare
- HQ
- Paterna, Spain
- Founded
- 2023
- Employees
- 4
- Website
- evolvingtherapeutics.es/
- Ownership
- Privately Held (backing)
Evolving Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Evolving Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Evolving Therapeutics in its N-PORT filings yet. We sweep new filings monthly.